Change the Future for Your Patients and Your Practice
The AdaptDx Pro® by MacuLogix® combines the game-changing science of dark adaptation with patient comfort and convenience.
Your patients will be impressed by the innovative technology of the headset. You and your team will appreciate how easily the AdaptDx Pro fits into your workflow. Everyone will welcome the peace of mind that comes from the early diagnosis and treatment of AMD.
Join the AMD Revolution
Customer Success Stories
Explore our collection of customer success stories to learn more about the benefits of dark adaptation testing for your patients and your practice. Read as your colleagues in eye care highlight how they utilize AdaptDx® technology as they work to find AMD, improve patient outcomes, and have a positive impact on their practice.
Practical Opportunities in AMD Management
The only constant is change – for the world, for eye care, and for the treatment and management of AMD.
Whether you have a strong AMD program, need to up your game, or are thinking about creating one, our latest e-book, Practical Opportunities in AMD Management, can provide you with updated information for improving patient outcomes and enhancing practice revenue.
This 16-page e-book features industry experts who share their knowledge and experience in diagnosing and monitoring AMD. It also includes short vignettes from various optometrists that provide real-world examples of how they’ve implemented dark adaptation testing, as well as advice for their colleagues.
Tour our Virtual Exhibit
Our interactive Virtual Exhibit allows you to meet the newest member of our team – Theia™, the on-board technician for the AdaptDx Pro® headset dark adaptometer. Theia will welcome you to the booth as you learn how tackling AMD can benefit your practice.
Explore the exhibit at your leisure – without any sales pressure – and see this amazing technology for yourself. When you are ready to learn more, just enter your ZIP code into the laptop in the booth to find your Regional Sales Executive.
Impaired Dark Adaptation: The Earliest Biomarker of AMD (video)
Before drusen are visible, an invisible layer of cholesterol builds up between the pigmented layer of the retina (RPE) and the elastic layer of Bruch’s membrane. These cholesterol deposits — basal laminar (BLamD) and basal linear (BLinD) — cause oxidative stress and inflammation, hindering nutrient transportation to photoreceptor cells. As photoreceptor cells die, it becomes harder for the eyes to adjust to the darkness, and night vision declines. This dark adaptation impairment is the first sign of age-related macular degeneration (AMD).
The cholesterol deposits grow over time. Where they become sufficiently thickened, the lesion becomes clinically detectable as a druse. The first visible druse caused by AMD is just the tip of the iceberg of these lesions.
Research has shown that impaired dark adaptation function can be detected at least three years before drusen are clinically evident, allowing for earlier diagnosis, treatment, and monitoring of AMD.
The Earliest Biomarker of Age-Related Macular Degeneration
Frequently Asked Questions
Find the answers to frequently asked questions about age-related macular degeneration, dark adaptation, and AdaptDx Pro® testing.